🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

344 results for “AVI” Clear

  1. Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups A, C, W-135 and Y conjugate vaccine, Prevenar 13 suspension for injection pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed), Rotarix oral suspension in pre-filled oral applicator Rotavirus vaccine, live, Infanrix hexa, Powder and suspension for suspension for injection. Diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), poliomyelitis (inactivated) (IP

    GlaxoSmithKline

    Infections, Meningococcal

    phase 2 small molecule active

    1 trial

  2. Opaganib

    RedHill Biopharma

    Coronavirus Infections

    phase 2 small molecule completed

    1 trial

  3. Oral hexavalent reassortant rotavirus attenuated live vaccine

    Sinovac Research and Development Co.,

    Rotavirus Gastroenteritis

    phase 2 mab active

    2 trials

  4. Ozempic 0.25 mg solution for injection in pre-filled pen, Ozempic 0.5 mg solution for injection in pre-filled pen, Ozempic 1 mg solution for injection in pre-filled pen

    The George Institute

    Craving for and use of chemsex-related drugs

    phase 2 small molecule active

    1 trial

  5. PALONOSETRON, Jakavi 10 mg tablets, ONDANSETRON, NETUPITANT, APREPITANT, PACRITINIB, Jakavi 5 mg tablets, SELINEXOR

    Karyopharm Therapeutics Inc

    moderate thrombocytopenia, JAK inhibitor-naïve myelofibrosis

    phase 2 small molecule active

    1 trial

  6. Paclitaxel 6 mg/ml Concentrate for Solution for Infusion, Paclitaxel 6 mg/ml Concentrate for Solution for Infusion, Carboplatin 10 mg/ml concentrate for solution for infusion, Tislelizumab, Paclitaxel 6 mg/mL concentrate for solution for infusion, Carboplatin 10 mg/ml concentrate for solution for infusion

    Fondazione Telethon ETS

    Resectable Locally Advanced Oral Cavity Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  7. Piromelatine (Neu-P11)

    Lacuna Pharma Pty Ltd

    idiopathic (isolated) Rapid Eye Movement Behavior Disorder

    phase 2 small molecule active

    1 trial

  8. Placebo to ISL, Placebo to MK-8507, Placebo to BIC/FTC/TAF, EMTRICITABINE, TENOFOVIR ALAFENAMIDE AND BICTEGRAVIR, islatravir, ulonivirine

    Merck Sharp and Dohme

    HIV-1 Infection

    phase 2 small molecule active

    1 trial

  9. Placebo to match DNTH103, Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups A, C, W-135 and Y conjugate vaccine, DNTH103, Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, component, adsorbed), Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups A, C, W-135 and Y conjugate vaccine, Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, c

    Dianthus Therapeutics, Inc. /DE/

    Generalized Myasthenia Gravis

    phase 2 small molecule active

    1 trial

  10. Povetacicept

    Vertex Pharmaceuticals (Australia) Pty.

    Myasthenia Gravis, Generalized

    phase 2 small molecule active

    1 trial

  11. Prednisone + Jakavi(ruxolitinib)

    Yung NA

    GVHD - Graft-Versus-Host Disease

    phase 2 small molecule active

    1 trial

  12. RAVICTI 1.1 g/ml oral liquid

    Pari Pharma GmbH

    Pyruvate dehydrogenase deficiency

    phase 2 small molecule active

    1 trial

  13. Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli)

    BRIGHT MINDS BIOSCIENCES INC.

    Human Papilloma Virus Infection

    phase 2 mab completed

    1 trial

  14. Ribavirin

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Hepatitis C

    phase 2 small molecule completed

    1 trial

  15. Riboflavin

    United Therapeutics Europe Ltd

    Keratolysis

    phase 2 small molecule completed

    1 trial

  16. Ritonavir

    Abbott Australasia Pty Ltd

    Sarcoma, Kaposi

    phase 2 small molecule completed

    1 trial

  17. Rotarix™

    GlaxoSmithKline

    Infections, Rotavirus

    phase 2 mab completed

    1 trial

  18. Ruxolitinib

    RIGEL PHARMACEUTICALS INC

    Coronavirus

    phase 2 small molecule completed

    1 trial

  19. SIKLOS PAEDIATRIC 50mg dispersible tablets

    THERAVIA

    Sickle Cell Disease

    phase 2 small molecule active

    1 trial

  20. SNDX-6352

    Syndax Pharmaceuticals

    Coronavirus

    phase 2 small molecule terminated

    1 trial

  21. SPR720

    Spero Therapeutics

    Mycobacterium Avium Complex

    phase 2 small molecule terminated

    1 trial

  22. Selinexor

    Karyopharm Therapeutics Inc

    Coronavirus Infection

    phase 2 small molecule completed

    2 trials

  23. Standard Cognitive Behavioral Treatment

    BRIGHT MINDS BIOSCIENCES INC.

    Substance-Related Disorders

    phase 2 other completed

    1 trial

  24. Study evaluating the efficacy of the treatment after targeting PD-L1 and TIGIT in tumors with tertiary lymphoid structures

    The George Institute

    Adult patients with a histologically confirmed TLS-positive advanced or metastatic NSCLC naïve from systemic treatment or previously treated with chemotherapy and PD1/PDL1 antagonist, and not having previously been treated with CD137 agonists or investigational immune checkpoint blockade therapies, including (but not limited) anti-TIGIT, anti-LAG3. Patients must have adequate organ function with a performance status (WHO 0-1; ECOG 0-1). Patients must not have active or history of autoimmune disease or immune deficiency. The pregnant or breastfeeding women will be excluded. Other eligibility criteria are described in the related section of the protocol.

    phase 2 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources